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DNA topoisomerase II (topo II) is a target for many anticancer
drugs, including etoposide and amsacrine. These drugs stabilize
the topo II-DNA cleavable complex, preventing religation of the
DNA strand. Breaking of double-stranded DNA subsequently
leads to cell death (Malonne and Atassi, 1997). Two distinct topo
II isoforms have been identified. The topo IIα gene, located on
chromosome 17q21–22 encodes a 170-kDa enzyme, and the Topo
IIβ gene located on chromosome 3p24, encodes a 180-kDa
enzyme (Tsai-Pflugfeder et al, 1988; Jenkins et al, 1992). These
two isoforms have different functions in DNA topography and the
cell cycle (Austin and Marsh, 1998; Tan et al, 1992). However,
both enzymes have been implicated in topo II-reactive drug action.
Anticancer drug resistance has been attributed to alteration of topo
II gene expression. Determining the importance of each isoform in
anticancer drug action and resistance may create novel approaches
to circumventing drug resistance and screening new isoform-
specific drugs. Initial studies will require cell lines that either lack
or express low levels of one of the topo II isoforms. We have previ-
ously shown that MDA-VP etoposide-resistant human breast
cancer cells express low levels of topo IIα compared
MDA parental cells (Zhou et al, 1999). Here we show that MDA-
VP and parental cells have comparable topo IIβ levels. MDA-VP
cells therefore provide a useful model to study the role of each
topo II isoform in drug sensitivity. The newly constructed adeno-
virus vector containing the human topo IIα gene (Ad-topo IIα ) has
made it possible to sensitize cells to topo IIα -reactive drugs. 
Our present study indicates that etoposide preferentially interacts
with the topo IIα isoform, while topo IIβ is the preferred target 
for amsacrine. These results confirm previously reported studies
on the interaction between the two topo II isoforms and topo 
II-targetting drugs (Errington et al, 1999). 
MATERIAL AND METHODS 
Cell lines 
MDA-MB-231 parental cells were obtained from American Type
Culture Collection (Manassas, VA, USA). MDA-VP etoposide-
resistant human breast cancer cells were initially derived and
cloned from MDA-parental cells as described previously
(Matsumoto et al, 1997). All cells were screened and found to be
free of Mycoplasma (Gen-Probe Co., San Diego, CA, USA). 
Infection of cells with Ad-topo IIα virus 
The Ad-topo IIα virus was constructed and purified as described
previously (Zhou et al, 1999). Cells were grown in logarithmic
phase and were infected with Ad-topo IIα at a multiplicity of
infection of 100 pfu cell. Cells were harvested by standard
methods after 48 h. 
Cytostasis assay 
A total of 5000 cells were seeded onto 96-well cell culture plates
and allowed to adhere overnight. Cells were treated with different
concentrations of etoposide or amsacrine (Sigma Co., St Louis,
MO, USA). Their antiproliferative activity was determined by the
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Thiazolyl blue (MTT) assay as described previously (Fan et al,
1994). 
Northern blot analysis 
Total RNA was extracted with Trizol Reagent (Life Technologies,
Inc., Grand Island, NY, USA). Then 20 µ g of RNA was elec-
trophoresed on a 1% formaldehyde/agarose gel and transferred to
a Hybond-N+ membrane (Amersham Corp., Arlington Heights, IL,
USA). Human topo IIα gene probe ZII69 (Tsai-Pflugfeder et al,
1988), topo IIβ gene probe F12 (Austin et al, 1993; Herzog et al,
1998), and a GAPDH probe were used for hybridization. Probes
were labelled using the Rediprime labelling system (Amersham). 
Western blot analysis 
The procedure involved 2 million cells, set up in a 100 mm dish,
and treated as indicated. Cells were washed with cold phosphate-
buffered saline (PBS) and lysed with buffer (50 mM Tris-HCl,
pH 8.0, 425 mM NaCl, 1% Nonidet P-40, 0.5% deoxyclolate,
0.1% SDS, 10 mM β -mercaptoethanol) containing protease
inhibitors. (Ganapathi et al, 1996) Then 50 µ g protein was run on a
7.5% SDS/polyacrylamide gel and transferred to a Hybond ECL
nitrocellulose membrane (Amersham). Human topo IIα antibody
(TopoGEN, Inc., Columbus, OH, USA), topo IIβ antibody
(PharMingen Inc., San Diego, CA, USA), and β -actin antibody were
used for protein detection with the ECL analysis system
(Amersham). 
Band-depletion immunoblotting assay 
The band-depletion immunoblotting assay was performed as
described previously (Zwelling et al, 1989). Cells were infected
with Ad-topo IIα or Ad-β -gal (control) for 48 h and then treated
with 200 µ M etoposide or 100 µ M amsacrine at 37 ˚C for 1 h as
indicated. Cell lysates were prepared in 2X Laemmli buffer by
sonication for 30 s and boiled for 5 min. Proteins were resolved on
a 7.5% SDS/polyacrylamide gel and immunoblotted using human
topo IIα , topo IIβ , and β -actin antibodies. 
RESULTS 
MDA-VP and parental cells were treated with various concentra-
tions of etoposide or amsacrine. Table 1 shows that MDA-VP cells
were 15-fold more resistant to etoposide than were MDA-parental
cells. In contrast, MDA-VP cells were only 2.2-fold more resistant
to amsacrine. To determine whether the differences in resistance
were related to expression of the topo II isoforms in these cells,
topo IIα and topo IIβ RNA and protein levels were measured. 
Topo IIα mRNA levels were lower in MDA-VP cells than in
MDA-parental cells (Figure 1A). Densitometric analysis showed
only 20% topo IIα gene expression in the etoposide-resistant
MDA-VP cells compared to the MDA-parent cells (Figure 1B,
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Table 1 Comparison of resistance to etoposide or amsacrine between
MDA-parent cells and MDA-VP cells.* 
Cells IC50
† for etoposide  IC50 for amsacrine 
(M ± SD)‡ (M ± SD)‡
MDA-parental cells 3.0 ± 0.2 µ M 5.6 ± 0.3 µ M 
MDA-VP cells 45.6 ± 2.0 µ M 12.8 ± 1.0 µ M 
Relative resistance of MDA-VP cells § 15.0-fold 2.2-fold
*Cytostasis was measured by MTT assay as described in Material and
methods. †IC50 is the concentration that inhibits 50% of cell growth. ‡M: mean
value from at least 3 experiments, SD: standard deviation. §The relative
resistance is calculated by dividing the IC50 of MDA-VP by IC50 of 
MDA-parent cells. 
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Figure 1 (A) Expression of topo IIα and topo IIβ RNA in MDA-parental cells, MDA-VP cells, and MDA-VP cells infected with Ad-topo IIα . Total RNA was
extracted from MDA-parental cells (lane 1), MDA-VP cells, (lane 2) and MDA-VP cells infected with Ad-topo IIα at 100 pfu/cell (lane 3). Northern blot analysis
was performed using topo IIα , topo IIβ and GAPDH probes. (B) Topo IIα and β mRNA expression was quantified using densitometric analysis. The relative
density at each point was calculated by dividing that value by the density in MDA-parent cells and adjusted by GAPDH loading control. The columns represent
the mean from 3 independent experiments; the bars represent the standard deviation
BJOC 01-1966 747-751  20/8/01  3:29 pm  Page 748upper panel). Topo IIβ mRNA levels were not significantly
different in the two cell types (Figure 1B, lower panel). Topo IIα
protein levels were also much lower in MDA-VP cells than in
MDA-parental cells, (Figure 2A and 2B, upper panel) while topo
IIβ protein levels were not significantly different in the 2 cell types
(Figure 2B, lower panel). 
To further explore the relationship between drug resistance and
isoform expression, MDA-VP cells were infected with the Ad-
topo IIα virus, then the topo II RNA and protein levels, as well as
drug sensitivity, were quantified. Topo IIα mRNA levels were
elevated after infection; however, topo IIβ levels were not signifi-
cantly altered (Figure 1). Topo IIα protein levels also increased in
MDA-VP cells after Ad-topo IIα infection, but topo IIβ protein
levels remained constant (Figure 2). The sensitivity of MDA-VP
cells to etoposide increased 4.5-fold after infection with Ad-topo
IIα . The IC50 of MDA-VP cells infected with Ad-topo IIα went
from 45.6 µ M to 10.1 µ M. By contrast, the sensitivity to
amsacrine only increased 1.3-fold following infection with Ad-
topo IIα (Table 2). Therefore, the increased sensitivity of cells 
to etoposide following topo IIα gene transfer correlated with
increased topo IIα levels but not with topo IIβ levels. 
A band-depletion immunoblotting assay was performed with
topo IIα and topo IIβ antibodies to analyze the interaction of the 2
isoforms with etoposide and amsacrine. Topo IIα band depletion
was seen following treatment with etoposide, while little
change was seen following amsacrine treatment (Figure 3, lanes
2,3, upper panel). In contrast, topo IIβ was more depleted in cells
treated with amsacrine than in cells treated with etoposide (Figure
3, lanes 2,3, middle panel). Densitometric analysis indicated that
etoposide induced 70% depletion of topo IIα protein and only 10%
depletion of topo IIβ protein (Figure 3, lane 2). Conversely,
amsacrine induced only a 10% reduction of topo IIα protein, but a
60% reduction of topo IIβ protein (Figure 3, lane 3). After infec-
tion of MDA-VP cells with Ad-topo IIα , topo IIα protein levels
were once again significantly increased (Figure 3, lane 4, upper
panel) with relatively no change in topo IIβ protein levels (Figure
3, lane 4, middle panel). Neither topo IIα protein levels nor topo
IIβ protein levels were significantly altered following infection
with Ad-β -gal (Figure 3, lane 7). The band-depletion pattern in
MDA-VP cells following infection with Ad-topo IIα (Figure 3,
lanes 5, 6) and Ad-β -gal (Figure 3, lanes 8, 9) was the same as that
seen in MDA-VP control cells (Figure 3, lanes 2,3). Etoposide
treatment induced a significant reduction in topo IIα , with little
change in topo IIβ . By contrast, treatment with amsacrine did not
affect the increased topo IIα protein levels in the MDA-VP-Ad-
topo IIα cells. 
DISCUSSION 
Topo II, a nuclear enzyme involved in a number of important
cellular processes, is the target for several anticancer drugs. The
specific roles of topo IIα and topo IIβ isoforms in the action of
these topo II-targetting drugs are still poorly understood. Our data
provide further evidence that topo IIα is the main target for etopo-
Drugs target different topoisomerase II isoforms 749
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Figure 2 (A) Comparison of protein levels in MDA-parental cells, MDA-VP cells, and MDA-VP cells infected with Ad-topo IIα . Protein was extracted from 
MDA-parental cells (lane 1), MDA-VP cells (lane 2), and MDA-VP cells infected with Ad-topo IIα (lane 3). Western blot analysis was performed using anti-
human topo IIα , topo IIβ , and β -actin antibodies. (B) Topo IIα and β protein expression was quantified using densitometric analysis. The relative density was
calculated compared with MDA-parent cells and adjusted by β -actin loading control. The columns represent the mean from 3 independent experiments; the bars
represent the standard deviation
Table 2 Enhancement of sensitivity to etoposide or amsacrine following
infection of MDA-VP cells with Ad-topo IIα * 
Cells IC50 for etoposide  IC50 for amsacrine 
(M ± SD) (M ± SD)
MDA-VP cells 45.6 ± 2.0 µ M 12.8 ± 1.0 µ M 
MDA-VP cells infected with Ad-topo IIα 10.1 ± 0.5 µ M 9.3 ± 0.4 µ M 
Sensitivity enhancement† 4.5-fold 1.3-fold
*MDA-VP cells were infected with Ad-topo IIα (100 pfu/cell) for 48 h, then
treated with different concentrations of etoposide or amsacrine. †Sensitivity
enhancement is calculated by dividing the IC50 of MDA-VP by IC50 of MDA-
VP with Ad-topo IIα . 
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MDA-VP cells. The etoposide sensitivity and resistance are more
related to topo IIα gene expression than to topo IIβ expression.
MDA-VP cells expressed lower levels of topo IIα RNA
and protein than MDA parental cells. In contrast, topo IIβ
RNA and protein levels were relatively the same in both cell types.
MDA-VP cells are more resistant to etoposide than to amsacrine
and this correlates to the topo IIα and topo IIβ protein levels.
Correlation between mRNA topo II levels and cell kill are not
always universal. The level of drug-stabilized cleavable complex
formation is the most important factor (Koo et al, 1999). Our
previous studies show that etoposide-induced topo IIα -DNA
cleavable complex formation is also significantly lower in MDA-
VP cells than in parental cells, supporting the hypothesis that low
levels of topo IIα account for the etoposide resistance of these
cells. Drug uptake and participation of P-glycoprotein or the
multiple drug-resistant associated protein do not play a role in
resistance of MDA-VP cells (Asano et al 1996). 
Transfer of the human topo IIα gene into MDA-VP cells using
an adenoviral vector increased topo IIα protein levels without an
appreciable change in topo IIβ protein levels. The topo IIα protein
produced following transduction was sensitive to etoposide but not
to amsacrine. Etoposide-induced cytotoxicity was enhanced 4.5-
fold in cells transduced with topo IIα , whereas amsacrine-induced
cytotoxicity did not change significantly. These results indicate
that topo IIα gene transfer does not alter topo IIβ expression and
that the enhanced sensitivity to etoposide is secondary to the
change in topo IIα . 
The involvement of topo IIβ in amsacrine sensitivity is also
supported by others. Herzog et al (1998) have shown that topo 
IIβ mRNA levels in HL60/AMSA amsacrine-resistant human
leukaemia cells are only 10% of those in HL-60 parental cells and
that topo IIβ protein is not detectable in HL60/AMSA cells.
However, these cells are sensitive to etoposide. Withoff et al
(1996) have additionally demonstrated that amsacrine resistance in
GLCA/AM3y cells, a subline of the human small cell lung
carcinoma cell line, is linked to a major decrease in topo IIβ
protein. Dereuddre et al were able to increase the sensitivity of a
Chinese hamster lung cell line to amsacrine by transfection with
the topo IIβ gene (Dereuddre et al, 1997). 
Topo IIβ have different tissue distribution. High levels of topo
IIα expression have been seen in aggressive proliferating tumours,
whereas topo IIβ appears to be expressed ubiquitously in quiescent
cells (Turley et al, 1997). Topo IIα is essential for survival of
eucaryotic cells (Wang, 1996), while topo IIβ does not appear to
be essential for either proliferation or survival (Yang et al, 2000;
Herzog et al, 1998). Such findings may help explain the greater
clinical utility of etoposide versus amsacrine. Each topo II isoform
appears to carry out a different cellular function and plays a
different role in drug resistance. It is important to understand 
how tumour cell sensitivity may be influenced by differential
expression of these two isoforms. 
In summary, our data indicate that topo IIα gene transfer does
not affect topo IIβ expression, and the ability to circumvent etopo-
side resistance using topo IIα gene transfer is secondary to
enhanced production of the drug-sensitive protein. These data
substantiate the hypothesis that etoposide preferentially targets
topo IIα , while amsacrine targets topo IIβ . In addition we have
shown that we can successfully manipulate topo IIα gene expres-
sion in cells without the problem of feedback inhibition previously
experienced by us and other laboratories (Asano et al, 1996). We
attributed this to our use of the strong cytomegalovirus promoter in
our adenoviral vector construct. This vector can be manipulated by
making mutations in specific parts of the gene and thus provide a
valuable tool with which to investigate the biology of human topo
IIα expression and function. 
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Figure 3 Band-depletion immunoblotting assay using topo IIα and topo IIβ antibodies. MDA-VP cells were treated with PBS buffer as a control (MDA-VP),
with 200 µ M etoposide (VP16), or with 100 µ M amsacrine (AMSA) for 1 h at 37˚C. Identical treatment was performed on MDA-VP cells 48 h after infection with
Ad-topo IIα (lanes 4–6) or Ad-β -gal (lanes 7–9). Topo II protein isoforms were extracted and quantified using a band-depletion immunoblotting assay with
human topo IIα , topo IIβ , and β -actin antibodies. The relative fold was calculated using densitometric analysis from 3 independent experiments. MDA-VP cells
were designated as 1.0 and calculations were adjusted according to the β -actin protein loading control
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